Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody

Authors

  • Fazel Shokri Department of Immunology, School of Public Health, Tehran University of Medical Sciences, |Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
  • Forough Golsaz-Shirazi Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran
  • Mohammad Mehdi Amiri Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran
  • Reza Hosseini-Ghatar Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran
  • Tahereh Soltantoyeh Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran
  • Tannaz Bahadori Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran
Abstract:

This article doesn't have abstract

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Ofatumumab: a novel monoclonal anti-CD20 antibody

Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...

full text

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab

Autophagy has been emerging as a novel cytoprotective mechanism to increase tumor cell survival under conditions of metabolic stress and hypoxia as well as to escape chemotherapy-induced cell death. To elucidate whether autophagy might also protect cancer cells from the growth inhibitory effects of targeted therapies, we evaluated the autophagic status of preclinical breast cancer models exhibi...

full text

Chimeric Antitenascin Monoclonal Antibody 81C6

1Department of Radiology, Duke University Medical Center, Durham, North Carolina; 2The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina; 3Department of Medicine, Duke University Medical Center, Durham, North Carolina; 4Department of Surgery, Duke University Medical Center, Durham, North Carolina; and 5Department of Pathology, Duke University Medica...

full text

Development of a novel anti ESAT-6 monoclonal antibody for screening of Mycobacterium tuberculosis.

Tuberculosis (TB) is a major global public health problem with an estimated one-third of the world's population infected with Mycobacterium tuberculosis, thus necessitating fast and accurate diagnosis of TB. However, the diagnosis of latent infection remains difficult due to the lack of a simple, reliable test for M. tuberculosis infection. The objective of the current study was to generate and...

full text

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

INTRODUCTION Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established. CASE REPORT The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a r...

full text

99mTc Direct radiolabeling of PR81, a new anti-MUC1 monoclonal antibody for radioimmunoscintigraphy

  Introduction: Monoclonal antibodies labeled mainly with 99mTc are being widely used as imaging agents in nuclear medicine. Recently PR81 was introduced as a new murine anti-MUC1 MAb against human breast carcinoma. This antibody reacts with the tandem repeat of 20-mer peptide of protein backbone, and is of IgG1 class, with an affinity of 2.19×10-8 M-1. Due to high sp...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 16  issue 1

pages  26- 42

publication date 2019-03-01

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023